

# Using the Azure Cielo™ Real-Time PCR System for SARS-CoV-2 viral RNA detection

## Introduction

The outbreak of severe acute respiratory syndrome 2 (SARS-CoV-2) responsible for the pandemic of 2020 has taken the lives of 4.39M people to date<sup>1</sup>. To help contain the virus and reduce the number of fatalities, rapid and reliable diagnosis is critical.

The 'gold standard' for COVID-19 detection relies upon a well-established technique called reverse transcription quantitative polymerase chain reaction, or RT-qPCR. Briefly, this procedure involves RNA extraction, reverse transcription into complementary DNA or cDNA, and quantification of the transcript (specific to the viral genome) with a thermal cycler in real-time.

For early detection and diagnosis, it is imperative that real-time PCR instruments are capable of measuring very small amounts of viral RNA. Researchers estimate that the limit of detection (LOD), or the lowest concentration of RNA detected with > 95% confidence, can be as little as 1 copy of viral RNA per  $\mu\text{L}^2$ . Therefore, in this technical note, we sought to determine the LOD for the Azure Cielo using SARS-CoV-2 RNA.

## Materials and methods

The LOD, or analytical sensitivity, of the Azure Cielo Real-Time PCR instrument was tested using the FDA approved COVID-19 genesig® Real-Time PCR assay as described in the instructions for use (IFU). The positive control template (PCT) provided with the kit was used to generate a six-point standard curve as follows:

Dilution #	Dilution factor	Copies per $\mu\text{L}$
0	Stock	$1.25 \times 10^5$
1	1/100	$1.25 \times 10^3$
2	1/100	$1.25 \times 10^1$
3	1/10	1.25
4	1/2	0.625
5	1/10	0.06

Table 1. PCT dilution series. Each dilution was measured in technical triplicate.

SARS-CoV-2 whole genomic RNA (Ref: 026N-03889) was obtained from the European Virus Archive-Global (EvaG) and a four-point serial dilution was generated as described in the IFU. Twenty replicates per dilution were measured.

The final composition of each reaction was:

- 8  $\mu\text{L}$  of sample (PCT or SARS-CoV-2 RNA)
- 10  $\mu\text{L}$  of oasis™ OneStep 2X RT-qPCR Master Mix
- 2  $\mu\text{L}$  COVID-19 Primer & Probe

The reactions were loaded into a 96-well plate and the following amplification protocol was used:

1. reverse transcription at 55°C for 10 min
2. initial denaturation (Taq activation) at 95°C for 2 min
3. denaturation at 95°C for 10 sec
4. annealing and extension at 60°C for 60 sec, followed by a plate read
5. steps 3–4 were repeated 45X in total

## Results and discussion

To correlate the number of copies of viral RNA/ $\mu\text{L}$  to Cq value, a standard curve from the PCT was generated using the dilution factors shown in Table 1 (Figure 1).

To determine the LOD, we compared the Cq values of SARS-CoV-2 RNA detected by the Cielo at dilution #'s 2–5 (Table 1). We found that at 12.5 copies/ $\mu\text{L}$ , 20/20 or 100% of the replicates were detected by the instrument and had a mean Cq of 30.49 (Figure 2, green). At 1.25 copies/ $\mu\text{L}$ , 20/20 (100%) of replicates were detected and had a mean Cq of 33.66 (Figure 2, yellow). At 0.625 copies/ $\mu\text{L}$ , 20/20 (100%) of the replicates were detected and had a Cq average of 34.80 (Figure 2, orange). At the final dilution of 0.06 copies/ $\mu\text{L}$ , 12/20 or 60% of the replicates were detected and the average Cq was 37.12 (Figure 2, red).

These results demonstrate that the LOD for the Cielo is 0.625 copies of SARS-CoV-2 RNA/ $\mu\text{L}$ , indicating that the Cielo can be used for rapid and reliable detection of COVID-19.




Figure 1. A six-point standard curve was used to estimate the number of copies of viral RNA/ $\mu\text{L}$ . The mean Cq value for each dilution is shown.




Figure 2. The number of copies of SARS-CoV-2 transcripts per  $\mu\text{L}$  as a function of Cq value. The dashed line represents the mean and error bars show the standard deviation ( $n=20$ ). At 0.06 copies/ $\mu\text{L}$ , 8 replicates were not detected (ND).

## References

- <https://www.nytimes.com/interactive/2021/world/covid-cases.html>
- Arnaut R, Lee RA, Lee GR, Callahan C, Yen CF, Smith KP, Arora R, Kirby JE. SARS-CoV2 Testing: The Limit of Detection Matters. *bioRxiv* [Preprint]. 2020 Jun 4:2020.06.02.131144. doi: 10.1101/2020.06.02.131144.

**Biozym**  
SCIENCE IS OUR BUSINESS  
[www.biozym.com](http://www.biozym.com)

**Biozym Scientific GmbH**  
Tel.: 05152 / 9020, Fax: 05152 / 2070  
Mail: [support@biozym.com](mailto:support@biozym.com)

**Biozym Biotech Trading GmbH**  
Tel.: 01 / 334 0156 0, Fax: 01 / 334 0156 88  
Mail: [support@biozym.com](mailto:support@biozym.com)



Biozym Scientific



@BiozymS



Biozym Scientific



Newsletter

**azure**  
biosystems

[www.azurebiosystems.com](http://www.azurebiosystems.com) • [info@azurebiosystems.com](mailto:info@azurebiosystems.com)

Copyright © 2021 Azure Biosystems. All rights reserved. The Azure Biosystems logo, Azure Biosystems®, and Cielo™ are trademarks of the Company. All other trademarks, service marks and trade names appearing in this brochure are the property of their respective owners.